Clinical Trials Should Include Finding Maintenance Dose, FDA’s Temple Says
Maintenance doses are not sufficiently studied in clinical trials, FDA Center for Drug Evaluation & Research Medical Policy Director Robert Temple, MD, said
You may also be interested in...
FDA's "Critical Path" initiative will redirect the agency's research funding towards identifying and alleviating some major barriers to drug development
FDA will begin a pilot program for end-of-Phase IIa meetings in advance of a draft guidance expected to be issued in early 2004
FDA believes that use of an exposure-response analysis to establish the optimal dose of GlaxoSmithKline's irritable bowel syndrome agent Lotronex would have prevented its withdrawal